Among patients with a baseline MADRS score of 12 , depressive symptom remission ( defined as MADRS score < 10 at LOCF endpoint ) was attained by 45.0 % of lurasidone-treated patients and 36.3 % of patients receiving placebo ( P < .05 ) .